Mycobacterium phocaicum

From WikiMD's WELLNESSPEDIA

Mycobacterium phocaicum is a species of bacteria belonging to the genus Mycobacterium. It is a non-tuberculous mycobacterium (NTM) and is considered a rare pathogen in humans.

Taxonomy[edit]

Mycobacterium phocaicum is a member of the Mycobacterium fortuitum complex, a group of rapidly growing, non-tuberculous mycobacteria. The species was first described in 2003 by Kazue Nakanaga and colleagues, who isolated it from a patient with a skin infection.

Characteristics[edit]

Like other mycobacteria, Mycobacterium phocaicum is a Gram-positive, acid-fast bacterium. It is a rapidly growing species, with colonies appearing on solid media within three days. The bacterium is capable of surviving in a wide range of environments, including water and soil.

Pathogenicity[edit]

Mycobacterium phocaicum is considered a rare pathogen in humans. It has been associated with skin and soft tissue infections, particularly in immunocompromised individuals. The bacterium has also been isolated from respiratory samples, although its role in lung disease is not well understood.

Treatment[edit]

Treatment of infections caused by Mycobacterium phocaicum can be challenging due to the bacterium's inherent resistance to many antibiotics. However, the species is typically susceptible to macrolides, quinolones, and aminoglycosides. Treatment regimens should be guided by susceptibility testing and often involve combination therapy with multiple antibiotics.

See also[edit]

References[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.